The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder strongly associated with obesity and excessive fat accumulation in the liver and pancreas leading to insulin resistance and hyperglycemia. While lifestyle modifications are the first-line approach to managing T2DM, many patients require...

Full description

Saved in:
Bibliographic Details
Main Authors: Mighty Kemelo, Phillip Moseki
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Results in Chemistry
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211715625001225
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850069879919476736
author Mighty Kemelo
Phillip Moseki
author_facet Mighty Kemelo
Phillip Moseki
author_sort Mighty Kemelo
collection DOAJ
description Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder strongly associated with obesity and excessive fat accumulation in the liver and pancreas leading to insulin resistance and hyperglycemia. While lifestyle modifications are the first-line approach to managing T2DM, many patients require oral hypoglycemic medications to regulate and maintain blood glucose levels. Although the precise mechanisms of action for these drugs remain unclear, emerging evidence suggests that they may exert their effects through the AMP-activated protein kinase (AMPK) and/or Sirtuin 1 (SIRT1) pathways. Activation of the AMPK pathway promotes fatty acid oxidation, suppresses cholesterol biosynthesis, and enhances glucose uptake. Similarly, SIRT1, an NAD+-dependent deacetylase, regulates many proteins involved in glucose homeostasis and insulin signaling. This review explores the therapeutic potential of AMPK and SIRT1 in T2DM. It provides an in-depth analysis of AMPK's role in T2DM pathogenesis and highlights the benefits of AMPK modulation by polyphenols. Additionally, it delves into the mechanisms of oral hypoglycemic drugs, emphasizing the significance of AMPK activation. Furthermore, the review discusses the impact of calorie restriction and SIRT1 activation in T2DM, considering both non-pharmacological interventions and synthetic SIRT1 activation as viable therapeutic options.
format Article
id doaj-art-9abcc23786c84ee789e4c294dbb889ca
institution DOAJ
issn 2211-7156
language English
publishDate 2025-03-01
publisher Elsevier
record_format Article
series Results in Chemistry
spelling doaj-art-9abcc23786c84ee789e4c294dbb889ca2025-08-20T02:47:39ZengElsevierResults in Chemistry2211-71562025-03-011410213910.1016/j.rechem.2025.102139The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus managementMighty Kemelo0Phillip Moseki1Department of Biomedical Sciences, Faculty of Medicine, University of Botswana, Botswana; Corresponding author at: Department of Biomedical Sciences, Faculty of Medicine, University of Botswana, Botswana.Department of Biological Sciences, Faculty of Science, University of Botswana, BotswanaType 2 diabetes mellitus (T2DM) is a chronic metabolic disorder strongly associated with obesity and excessive fat accumulation in the liver and pancreas leading to insulin resistance and hyperglycemia. While lifestyle modifications are the first-line approach to managing T2DM, many patients require oral hypoglycemic medications to regulate and maintain blood glucose levels. Although the precise mechanisms of action for these drugs remain unclear, emerging evidence suggests that they may exert their effects through the AMP-activated protein kinase (AMPK) and/or Sirtuin 1 (SIRT1) pathways. Activation of the AMPK pathway promotes fatty acid oxidation, suppresses cholesterol biosynthesis, and enhances glucose uptake. Similarly, SIRT1, an NAD+-dependent deacetylase, regulates many proteins involved in glucose homeostasis and insulin signaling. This review explores the therapeutic potential of AMPK and SIRT1 in T2DM. It provides an in-depth analysis of AMPK's role in T2DM pathogenesis and highlights the benefits of AMPK modulation by polyphenols. Additionally, it delves into the mechanisms of oral hypoglycemic drugs, emphasizing the significance of AMPK activation. Furthermore, the review discusses the impact of calorie restriction and SIRT1 activation in T2DM, considering both non-pharmacological interventions and synthetic SIRT1 activation as viable therapeutic options.http://www.sciencedirect.com/science/article/pii/S2211715625001225Type 2 diabetes mellitus (T2DM)Natural polyphenolsAMP-activated protein kinase (AMPK)Oral hypoglycemic drugsSirtuin-1 (SIRT1)Sirtuin-activating compounds (STACs)
spellingShingle Mighty Kemelo
Phillip Moseki
The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management
Results in Chemistry
Type 2 diabetes mellitus (T2DM)
Natural polyphenols
AMP-activated protein kinase (AMPK)
Oral hypoglycemic drugs
Sirtuin-1 (SIRT1)
Sirtuin-activating compounds (STACs)
title The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management
title_full The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management
title_fullStr The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management
title_full_unstemmed The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management
title_short The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management
title_sort ampk sirt1 axis redefining type 2 diabetes mellitus management
topic Type 2 diabetes mellitus (T2DM)
Natural polyphenols
AMP-activated protein kinase (AMPK)
Oral hypoglycemic drugs
Sirtuin-1 (SIRT1)
Sirtuin-activating compounds (STACs)
url http://www.sciencedirect.com/science/article/pii/S2211715625001225
work_keys_str_mv AT mightykemelo theampksirt1axisredefiningtype2diabetesmellitusmanagement
AT phillipmoseki theampksirt1axisredefiningtype2diabetesmellitusmanagement
AT mightykemelo ampksirt1axisredefiningtype2diabetesmellitusmanagement
AT phillipmoseki ampksirt1axisredefiningtype2diabetesmellitusmanagement